|Bid||4.9300 x 0|
|Ask||4.9500 x 0|
|Day's Range||4.9400 - 4.9700|
|52 Week Range||4.9200 - 6.2000|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||15.49|
|Earnings Date||Mar 22, 2023 - Mar 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.09|
Key Insights Significant control over Knight Therapeutics by retail investors implies that the general public has more...
MONTREAL, March 16, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2022 financial results on Thursday, March 23, 2023 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, March 23, 2023 Time: 8:30 a.m. ET Telephone: Toll
Four TSX biotech stocks could deliver outsized gains in 2023, as they are poised to break through the market soon. The post 4 Biotech Stocks That Could Break Through the Market appeared first on The Motley Fool Canada.